Summit Therapeutics to Participate in Upcoming Investor Events

Summit Therapeutics plc  (‘Summit’ or the ’Company’)

Summit Therapeutics to Participate in Upcoming Investor Events

Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two upcoming investor events.

• BIO Investor Forum, Mr Glyn Edwards is speaking on the panel “Using Microbiome-Based Therapies to Improve Patient Outcomes,” 10:45am PDT, 17 October 2018 in San Francisco, CA
• BTIG Biotech Conference, 25 October 2018 in New York City

At these events, management will conduct one-on-one meetings; there will be no podium presentations.

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking
Panmure Gordon (Joint Broker)	Tel:	[phone]
Freddy Crossley, Corporate FinanceJames Stearns, Corporate Broking
MSL Group (US)	Tel:	[phone]
Jon Siegal		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Jessica Hodgson /		[e-mail]
Lindsey Neville

-END-